title: Evaluation of the endothelial cell antibodies in serum and perilymphatic fluid of cochlear implanted children with sensorineural hearing loss.
abstract: BACKGROUND
  Serum Anti endothelial Cell Antibodies (AECAs) play a prominent role in idiopathic Sensorineural Hearing Loss (SNHL) in that they induce vascular damage (immune mediated). The of the current study is To compare AECAs in serum and perilymphatic fluid of idiopathic SNHL children (<15y) undergoing cochlear implant surgery.
  
  
  METHODS
  This was a cross sectional study performed in the cochlear implant ward in Rasoul Akram hospital, Tehran, Iran (2008 -2010) on 99 SNHL children undergoing cochlear implant surgery. The data collected from47 idiopathic and 52 non-idiopathic SNHL cases. AECAs were measured by indirect immuno fluorescence assay and compared in sera and perilymphatic fluids between the two groups. P-value < 0.05 was considered significant.
  
  
  RESULTS
  Idiopathic SNHL was diagnosed in 47.5% of cases. Positive AECA results in serum and perilymphatic fluid were 10% and 12%, respectively. Although AECA results in perilymphatic fluids were different between idiopathic and non-Idiopathic SNHL patients (PV < 0.05), AECAs in serum showed no significant difference between the two (PV = 0.1). No significant difference was detected between the mean age of idiopathic and non-idiopathic SNHL patients with positive AECAs in serum and perilymphatic fluids (PV = 0.2; PV = 0.2).
  
  
  CONCLUSIONS
  Idiopathic SNHL was diagnosed in 47.5% of studied cases. Idiopathic SNHL has a poor out come in children. In cases with idiopathic SNHL, finding AECAs in perilymphatic fluids are more valuable than in the serum. We suggest that serum and perilymphatic fluids testing for AECAs would be helpful in management of idiopathic SNHL cases. Specific immunosuppressive treatments for selected cases suffering from Idiopathic SNHL (only in those older than 5) might be successful in disease management. However, this theory should first be validated by randomized clinical trials.
authors.affiliation: ENT, Head & Neck Surgery Research Center, Rasoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Farhadi
authors.affiliation: Research Center of Pediatric Infectious Diseases, Hazrat Rasul Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Samileh
authors.initials: S
authors.lastname: Noorbakhsh
authors.affiliation: Research Center of Pediatric Infectious Diseases, Hazrat Rasul Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Azardokht
authors.initials: A
authors.lastname: Tabatabaei
authors.affiliation: ENT, Head & Neck Surgery Research Center, Rasoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Ahamad
authors.initials: A
authors.lastname: Daneshi
authors.affiliation: ENT, Head & Neck Surgery Research Center, Rasoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Sahar Ghavidel
authors.initials: SG
authors.lastname: Darestani
authors.affiliation: ENT, Head & Neck Surgery Research Center, Rasoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Emam
authors.initials: E
authors.lastname: Jomeh
keywords: Cochlear Implant; Endothelial Cell Antibodies; Idiopathic Sensorineural Hearing Loss (ISNHL); Indirect Immuno Fluorescence Assay; Sensoryneural Hearing Loss (SNHL)